Amgen Inc. (AMGN)
NASDAQ: AMGN · Real-Time Price · USD
289.63
-0.42 (-0.14%)
At close: Jun 18, 2025, 4:00 PM
289.01
-0.62 (-0.21%)
After-hours: Jun 18, 2025, 4:54 PM EDT
Amgen Revenue
Amgen had revenue of $8.15B in the quarter ending March 31, 2025, with 9.43% growth. This brings the company's revenue in the last twelve months to $34.13B, up 15.56% year-over-year. In the year 2024, Amgen had annual revenue of $33.42B with 18.57% growth.
Revenue (ttm)
$34.13B
Revenue Growth
+15.56%
P/S Ratio
4.57
Revenue / Employee
n/a
Employees
n/a
Market Cap
155.74B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 33.42B | 5.23B | 18.57% |
| Dec 31, 2023 | 28.19B | 1.87B | 7.09% |
| Dec 31, 2022 | 26.32B | 344.00M | 1.32% |
| Dec 31, 2021 | 25.98B | 555.00M | 2.18% |
| Dec 31, 2020 | 25.42B | 2.06B | 8.83% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 410.06B |
| Johnson & Johnson | 89.33B |
| Merck & Co. | 63.92B |
| AbbVie | 57.37B |
| AstraZeneca | 54.98B |
| Novartis AG | 53.22B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
AMGN News
- 8 hours ago - AMGEN'S PHASE 2 MARITIDE DATA TO BE PRESENTED AT THE AMERICAN DIABETES ASSOCIATION 85TH SCIENTIFIC SESSIONS - PRNewsWire
- 1 day ago - Democrats press Pfizer, J&J and others over low tax bills and lobbying as Senate debates Trump's plan - CNBC
- 4 days ago - Amgen: Imdelltra Data And Q1 Results Impress - Seeking Alpha
- 7 days ago - Amgen Inc. (AMGN) Presents at Goldman Sachs 46th Annual Global Healthcare Conference Transcript - Seeking Alpha
- 12 days ago - Amgen's Strategic Path - Navigating Patent Expiries With Promising New Therapies - Seeking Alpha
- 13 days ago - AMGEN TO PRESENT AT GOLDMAN SACHS 46TH ANNUAL GLOBAL HEALTHCARE CONFERENCE - PRNewsWire
- 15 days ago - Healthy Returns: AstraZeneca, Pfizer, Gilead and other drugmakers release promising cancer drug data at ASCO - CNBC
- 16 days ago - IMDELLTRA® SIGNIFICANTLY REDUCED RISK OF DEATH BY 40% IN SMALL CELL LUNG CANCER PATIENTS - PRNewsWire